Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
Ranitidine, previously sold under the brand name Zantac [a] among others, is a medication used to decrease stomach acid production. [12] It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [12] It can be given by mouth, injection into a muscle, or injection into a vein.
In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after NDMA was found in samples of the drug.
Zantac was first marketed in 1981, [7] and it was described in 1989 as "one of the most expensive drugs on the market", [8] and "the world's biggest-selling prescription drug". [9] Addiction to taking it ("a habit") was how some of its users described Zantac. [ 10 ]
Drug coupon advocates argue that coupon programs enhance medication adherence by reducing or eliminating drug copays. [2] As of 2008, the U.S. Food and Drug Administration (FDA) was planning a study to see if coupons make patients overlook drug risks and side effects in their effort to save money. [2] All medicines come with a certain level of ...
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. The drug, approved over four decades ago, was the world's ...
The French pharmaceutical company Sanofi says it has reached an agreement to resolve 4,000 cases in the U.S., in which plaintiffs are linking the discontinued heartburn drug Zantac — and its ...
Zantac commanded a premium over generic ranitidine drugs. Glaxo Group owned the ranitidine patent and would have owned it even if the appellant had been in an arm's length relationship. Without the License Agreement, the appellant would not have been in a position to use the ranitidine patent and the Zantac trademark.